Author Archives: admin


Stem Cell Clinic > Articles by: admin

Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) – Good Night, Good Hockey

By Adult Stem Cells

Global Stem Cell Reconstructive Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal. However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide. Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologous o Bone Marrow o Adipose Tissue o Blood Syngeneic Other Global Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem Cell Global Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn Other Global Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute Others Global Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA) Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

Global Stem Cell Reconstructive Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/54688

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info: Name: Vikas Godage Organization: MAXIMIZE MARKET RESEARCH PVT. LTD. Email: sales@maximizemarketresearch.com Website:www.maximizemarketresearch.com

Visit link:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Good Night, Good Hockey

Coronavirus Thursday update: UMN announces new stem cell treatment – TwinCities.com-Pioneer Press

By Stem Cell Medical Center

Doctors at the University of Minnesota are the first in the U.S. to treat a critical COVID-19 patient suffering from lung failure using stem cells.

A Food and Drug Administration-approved study will examine a new treatment using mesenchymal stem cells to intervene when a COVID-19 patients immune system becomes overactive and can lead to organ damage and often lung failure. This cytokine storm has been one of the more perplexing and fatal complications of a coronavirus infection.

The inflammation seen in patients with severe COVID-19 can be devastating, Dr. David Ingbar, a critical care and pulmonary physician at the M Health Fairview University of Minnesota Medical Center, said in a statement. The cytokine storm can rapidly lead to shock, massive fluid buildup in the tissues, and direct severe tissue injury, most often in the lungs.

A team of researchers at the university developed the treatment and are leading a study of its effectiveness with other clinicians around the country. Mesenchymal stem cells have been used successfully with other inflammatory conditions including in COVID-19 patients in Italy and China.

Researchers hope the stem cells will slow the cytokine storm and protect lung tissue from damage.

In order to determine the real benefit of MSCs in these very ill patients, patients will be randomized to receive three doses of MSC 48 hours apart or a placebo solution, said John E. Wagner, MD, cancer researcher and director of the Institute for Cell, Gene and Immunotherapy at the University of Minnesota.

The cells being used in this treatment were produced at the universitys molecular and cellular therapeutics center which develops materials such as cells, tissues, antibodies and proteins to be used in clinical trials.

The new treatment being studied at the University of Minnesota was announced as state health officials recorded seven new COVID-19 fatalities on Thursday. Those whose deaths were reported ranged in age from their 40s to their 90s.

The states death toll has reached 1,685 people with another 46 fatalities suspected to have been caused by COVID-19, but the patient did not have a positive coronavirus test.

With 697 new cases announced Thursday, Minnesota now has 62,993 laboratory-confirmed infections with cases in all 87 counties. Most patients are in the Twin Cities metro, but rural counties with meat processing facilities have the most cases per capita.

Health officials reported the results of 15,271 tests Thursday, a marked increase from earlier this week when the number of test results was lower than average.

Minnesota has screened 1.2 million samples from 963,096 patients since local testing started in March. The test positivity rate stands at about 5.3 percent.

Originally posted here:
Coronavirus Thursday update: UMN announces new stem cell treatment - TwinCities.com-Pioneer Press

Cell Separation Technologies Market Research Report by Technology, by Application, by End User – Global Forecast to 2025 – Cumulative Impact of…

By Stell Cell Research

August 13, 2020 04:36 ET | Source: ReportLinker

New York, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Separation Technologies Market Research Report by Technology, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913778/?utm_source=GNW

The Global Cell Separation Technologies Market is expected to grow from USD 5,347.52 Million in 2019 to USD 12,724.42 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 15.54%.

Market Segmentation & Coverage: This research report categorizes the Cell Separation Technologies to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the Cell Separation Technologies Market studied across Fluorescence-activated Cell Sorting, Immunomagnetic Cell Separation, and Microfluidic Cell Separation.

Based on Application, the Cell Separation Technologies Market studied across Cancer Research, Immunology, and Stem Cell Research.

Based on End User, the Cell Separation Technologies Market studied across Biotechnology and Pharmaceutical Companies and Hospitals and Diagnostic Laboratories.

Based on Geography, the Cell Separation Technologies Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Separation Technologies Market including BD Biosciences, Life Technologies Corporation, Merck Millipore, Miltenyi Biotec GmbH, STEMCELL Technologies, Inc., and Terumo BCT, Inc..

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cell Separation Technologies Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Cell Separation Technologies Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Separation Technologies Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Separation Technologies Market? 4. What is the competitive strategic window for opportunities in the Global Cell Separation Technologies Market? 5. What are the technology trends and regulatory frameworks in the Global Cell Separation Technologies Market? 6. What are the modes and strategic moves considered suitable for entering the Global Cell Separation Technologies Market? Read the full report: https://www.reportlinker.com/p05913778/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Excerpt from:
Cell Separation Technologies Market Research Report by Technology, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of...

Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil – Business Wire

By Stell Cell Research

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase III study of lenzilumab in patients with COVID-19 in Brazil.

This study, now set to begin recruiting patients in Brazil, follows the same protocol approved by the US Food and Drug Administration in April a multicenter, randomized, placebo-controlled, double-blinded clinical trial focused on hospitalized severe and critical adult COVID-19 patients at high risk of disease progression. Humanigen is working with Clinical Trial & Consulting (CTI), recently named the top global contract research organization, to conduct this trial in Brazil.

Cameron Durrant, MD, MBA, chief executive officer of Humanigen, said, COVID-19 is a global crisis and we are committed to offering assistance to patients across the world that are impacted by the pandemic. We hope that expanding the study of lenzilumab to research centers in Brazil, a country with surging rates of COVID-19, will offer patients much needed access to a leading COVID-19 therapeutic candidate.

Currently, Brazil has the second highest reported rates of COVID-19 infection in the world, second only to the US.

Access to clinical trials is critical for healthcare providers in the fight against COVID-19, remarked Timothy Schroeder, chief executive officer of CTI. We are proud to collaborate with our colleagues at Humanigen to extend the reach of the Phase III study of lenzilumab and bring a potential treatment option to those in need.

More details on Humanigens programs in COVID-19 can be found on the companys website at http://www.humanigen.com under the COVID-19 tab, and details of the US Phase III potential registration study can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04351152.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO) recently named #1 CRO in the world for quality, delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTIs focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit http://www.ctifacts.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations surrounding our ongoing and anticipated clinical trial activities in the United States and Brazil and our operational, research, development or commercialization activities for lenzilumab and the other product candidates in our current pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

The rest is here:
Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil - Business Wire

Global Hunter Syndrome Treatment Market was valued at approximately USD 927.9 million in 2019, and is expected to generate revenue of around USD…

By Stell Cell Research

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hunter Syndrome Treatment market.

Trusted Business Insights presents an updated and Latest Study on Hunter Syndrome Treatment Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hunter Syndrome Treatment market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hunter Syndrome Treatment Market by Treatment (Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and Others)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 2029

Abstract

The report covers forecast and analysis for the hunter syndrome treatment market on a global and regional level. The study provides historic data from 2016 to 2019 along with forecast from 2020 to 2026 based on revenue (USD Million). The study includes drivers and restraints for the hunter syndrome treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hunter syndrome treatment market on a global as well as regional level.

In order to give the users of this report a comprehensive view on the hunter syndrome treatment market we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the hunter syndrome treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new indication launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the hunter syndrome treatment market on global and regional basis.

The study provides a crucial view on the hunter syndrome treatment by segmenting the market based on treatment and region. All the segments of hunter syndrome treatment market have been analyzed based on present and future trends and the market is estimated from 2016 to 2026.

The global demand for hunter syndrome treatment market is driven by expected approval of new therapies, growing research and development activities, and extended life expectancy. However, lack of awareness and high cost may act as restraining factors for the market growth in the coming years. Increasing collaboration and technological advancements are projected to bring new growth avenues for market players during the forecast timeframe.

The hunter syndrome treatment market has been divided into treatment and region. Based on treatment, global hunter syndrome treatment market is segmented into Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and others. Market was dominated by Enzyme Replacement Therapy (ERT) segment in 2019 and is projected to retain its dominance over the forecast timeframe.

North America held largest revenue share of the global hunter syndrome treatment market in 2018. This large share is attributed to government funding, growing awareness and presence of key players in this region. Europe was second leading regional market in terms of revenue. Availability of developed infrastructure, increasing geriatric population, and growing awareness are major factors that support market growth in this region. Asia Pacific region is projected to be rapidly growing regional market for hunter syndrome treatment. Increasing chronic disease prevalence and geriatric population base, economic development, improvement of healthcare infrastructure, growing awareness are major factors attributing to the swift growth in this region. Moderate growth is projected in Latin America region over the forecast period. Middle East and Africa will witness sluggish growth in the coming years.

Major players in hunter syndrome treatment market are GC Pharma, Takeda Pharmaceutical Company, RegenxBio Inc., JCR Pharmaceuticals Co Ltd., Sangamo Therapeutics, Inc., Inventiva S.A., ArmaGen Inc, Esteve, Bioasis Technologies Inc., and Denali Therapeutics Inc among others.

The report segment of global hunter syndrome treatment market as follows:

Global Hunter Syndrome Treatment Market: Treatment

Hematopoietic Stem Cell Transplant (HSCT) Enzyme Replacement Therapy (ERT) Others

Global Hunter Syndrome Treatment Market: By Region

North America

The U.S. Canada

Europe

France The UK Spain Germany Italy Rest of Europe

Asia Pacific

China Japan India South Korea Southeast Asia Rest of Asia Pacific

Latin America

Brazil Mexico Rest of Latin America

Middle East & Africa

GCC South Africa Rest of Middle East & Africa

Looking for more? Check out our repository for all available reports on Hunter Syndrome Treatment in related sectors.

Quick Read Table of Contents of this Report @ Hunter Syndrome Treatment Market by Treatment (Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and Others)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 2029

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

More:
Global Hunter Syndrome Treatment Market was valued at approximately USD 927.9 million in 2019, and is expected to generate revenue of around USD...

Lowrie to have injections for knee pain relief – MLB.com

By Platelet Rich Plasma Injections

NEW YORK -- Jed Lowrie's 18-month injury saga took another turn on Wednesday, when the team announced the infielder will undergo a series of platelet-rich plasma and stem cell injections. Lowries timeline to return to the Mets will depend upon the outcome of that treatment. Its almost like a progression

NEW YORK -- Jed Lowrie's 18-month injury saga took another turn on Wednesday, when the team announced the infielder will undergo a series of platelet-rich plasma and stem cell injections. Lowries timeline to return to the Mets will depend upon the outcome of that treatment.

Its almost like a progression of injections and well see how everything responds, and [if] the pain goes away and hes able to join us at some point this season, Mets manager Luis Rojas said. Thats the plan.

The injection regimen was presented to Lowrie as a course of therapy after examinations from both Mets physician Dr. David Altchek and an independent, third-party doctor. Lowrie has been unable to play due to PCL laxity, a loosening of a left knee ligament that causes him pain when he runs. Although Lowrie feels some relief from the pain when he wears a rehab brace on his knee, the brace is too large and restricting for him to wear in games.

Until Lowrie can play with a smaller, more mobile brace, he will not come off the 45-day injured list. He is not eligible to come off anyway until Sept. 3.

Lowrie, 36, has taken just eight plate appearances since signing a two-year, $20 million contract in Jan. 2019. He has spent the vast majority of his tenure on the IL due to left knee trouble and a right calf strain. Lowrie initially sustained a sprained left knee capsule in Feb. 2019, before the team revealed that he was also battling more general, undefined left side issues.

Only last month did the Mets announce the updated PCL laxity diagnosis for Lowrie. Rojas said he was unsure if Lowrie, who was unavailable for comment, considered surgery or only the injection regimen.

Even if Lowrie can make it back in September, he will find playing time hard to come by. The Mets feature a crowded middle infield with Amed Rosario, Andrs Gimnez, Robinson Can and others all jockeying for reps. J.D. Davis has become the starter at third base, one of Lowries primary positions, while Gimnez has developed into an early National League Rookie of the Year candidate at second and short. Given his physical issues, it seems unlikely Lowrie would contribute anywhere other than at designated hitter, which is Dominic Smiths primary position.

From the trainers room Starting pitcher Michael Wacha (right shoulder inflammation) restarted a throwing program Tuesday at Citi Field, playing catch at distances up to 75 feet. He felt better, according to Rojas, but he will miss at least two starts on the IL. For now, Robert Gsellman has taken Wachas rotation spot.

Can (left adductor strain) could return from the IL as soon as hes eligible on Friday. Can was scheduled to play in a simulated game Wednesday at the Mets alternate site in Brooklyn, which Rojas called another step ahead for the veteran second baseman. When Can returns, the Mets will have to be creative to find playing time for Gimnez.

Shortstop sidelined Rosario was out of the lineup for a second straight game on Wednesday due to the lingering effects of a stomach bug, though he was available off the bench. Gimnez filled in at shortstop.

Everyday Daz The key to Edwin Dazs recent run of success out of the bullpen? Pitching more often.

When the Mets removed Daz from the closers role last week, he requested that the team use him more frequently than once every four or five days. Rojas listened, deploying Daz five times in a 10-day stretch from Aug. 2-11, and the reliever responded with 10 strikeouts and one walk over five scoreless innings.

Now that Ive been pitching more consecutively and more often, I feel like my pitches are all sharp, Daz said through an interpreter. But in regards to closing, thats not my decision. Im open to pitching whatever inning they tell me to come in -- whether its the sixth, seventh, eighth -- it doesnt matter to me. As long as they put the ball in my hands, Ill be ready to help the team.

Since Dazs unofficial demotion, Rojas has exclusively turned to Seth Lugo in save situations. The team is taking a committee approach, however, making it possible for Daz to garner more save chances again if he keeps pitching well.

Anthony DiComo has covered the Mets for MLB.com since 2007. Follow him on Twitter @AnthonyDiComo, Instagram and Facebook.

Read the original post:
Lowrie to have injections for knee pain relief - MLB.com

PRP versus Hyaluronic Acid Injections for Knee OA: Cost-Effectiveness Analysis – DocWire News

By Platelet Rich Plasma Injections

A study compared the cost-effectiveness of a series of three intra-articular platelet-rich plasma (PRP) injections versus hyaluronic acid (HA) viscosupplementation to treat symptomatic osteoarthritis (OA) of the knee.

Level one outcome data on PRP or HA injections in symptomatic knee OA patients through 2015 were used to collect health utility values. Costs were calculated using typical charges incurred by symptomatic knee OA patients treated at a large private orthopedic practice with a series of either PRP or HA injections. The health utility values and costs were the basis for an expected-value decision analysis model.

Per the model, the cost per quality-adjusted life year (QALY) of a series of PRP injections was $8,635.23/QALY compared with $5,331.75/QALY for a series of HA injections. While the series of PRP injections had a higher initial cost than the HA injections seriesa $1,433.67 differencethe PRP injections series was more effective, yielding a higher utility value, compared with the HA injections series at one year (0.69 vs. 0.58, respectively; P=0.0062). Using PRP injections instead of HA injections was associated with an incremental cost-effectiveness ratio of $12,628.15/QALY.

While a series of either PRP ($8,635.23/QALY) or HA ($5,331.75/QALY) injections for the treatment of symptomatic knee osteoarthritis would be considered cost-effective (cost/QALY <$50,000), PRP injections were not more cost-effective than HA. However, PRP was significantly more effective at one year, and being associated with an Institute for Clinical and Economic Review of $12,628.15/QALY when compared with HA, a series of PRP injections should be considered a reasonable and acceptable alternative to HA injections for the treatment of symptomatic knee OA, the authors concluded.

Read the original post:
PRP versus Hyaluronic Acid Injections for Knee OA: Cost-Effectiveness Analysis - DocWire News

Yes, People Are Reportedly Losing Hair Due to Stress From the Pandemic – POPSUGAR

By Platelet Rich Plasma Injections

As the year progresses and the novel coronavirus continues to upend everyday life, there's still a lot more we're learning about the virus and its side effects. For example, recent research has shown that hair loss is common among those who have recovered from the virus even actress Alyssa Milano revealed via Twitter that her hair has been falling out in clumps following her experience with COVID-19 though it also appears to be a common experience among those who haven't contracted the virus but are affected by the stress of the pandemic directly.

"I'm based in California, so the reopening of our salons has been a slower process than most states," celebrity hairstylist Carrera Alvarez told POPSUGAR. "One thing I'm hearing from my clients is concern about hair loss from stress, which is very real. We're living in a superstressful time, and that can lead to [potentially] losing more hair."

This type of hair loss is known as telogen effluvium, which, as a previous POPSUGAR article says, is "caused by physiologic stress to the body following conditions like anemia, low iron, surgery, general anesthesia, changes in hormones, or others." It's essentially stress-related hair loss, and it happens when the hair is pushed into the resting phase but doesn't enter the growth phase following a highly stressful event. "Anything that your body deems a stress physical or psychological will cause a person to develop a telogen effluvium," dermatologist Sapna Palep, MD, told POPSUGAR.

Dr. Palep has experienced telogen effluvium five times so far; two of them occurred after giving birth, while the others happened after three separate stressful events. According to her, most stress-related hair loss can linger for up to six months following whatever triggered it and can take up to one full year for the hair to recover. The good news is that this type of hair loss is usually temporary and can be treated with topical products and in-office procedures.

"In my office, I treat patients with hair loss with PRP (platelet-rich plasma) therapy, which uses injections of a concentration of a patient's own platelets to restore and accelerate hair growth," Dr. Palep said. "Treatments are done once a month for three months and every six months thereafter for maintenance. It's highly effective, and I've undergone PRP therapy myself for my hair loss."

If PRP isn't as accessible for you, both Alvarez and Dr. Palep have alternative hair-loss treatments they'd recommend turning to. "My go-to is Nioxin. It's the number one brand for thinning hair and known globally as a trusted brand," Alvarez said. "I start [my clients] on a System Kit to create a solid foundation for healthy growing hair." Meanwhile, Dr. Palep is a big fan of Nutrafol and the results it's been proven to show.

"I think it has a unique grouping of ingredients compared to its competitors," she said. For topical therapy, though, Dr. Palep recommends using Midoxil. "It's available without a prescription as a two percent solution, a five percent solution, and a five percent foam," she said. "I typically recommend five percent because studies support that it has somewhat greater efficacy. It works by increasing the window of time that a hair follicle is in its anagen (growth) phase, shortening the window of the telogen (resting/nongrowing) phase, and enlarging miniaturized follicles."

Continue reading here:
Yes, People Are Reportedly Losing Hair Due to Stress From the Pandemic - POPSUGAR

Advisory Body Backs MesoBlast Therapy for Transplant Complication – Xconomy

By Stem Cell Treatment

Xconomy New York

An FDA advisory committee Thursday voted 9-1 to recommend that the agency approve a stem cell therapy developed by MesoBlast as a treatment for acute graft-versus-host disease (aGVHD) in children. The panel weighed the need for a new way to address the potentially fatal condition against shortcomings of the clinical trial the Australian biotech conducted to evaluate the investigational cell therapy.

Shares in (NASDAQ: MESO), which fell more than 30 percent earlier in the week after the FDA released briefing documents ahead of the committees meeting, closed up 51 percent Friday at $17.88 apiece compared to $11.81 at market close Wednesday. (Trading was halted on Thursday.)

The MesoBlast cell therapy, remestemcel-L (Ryoncil), is made from mesenchymal cells taken from healthy donors. The properties of these cells, which dont prompt an immune reaction, allow them to be used as an off-the-shelf treatment without accompanying immunosuppressants that put patients at greater risk for infection, among other side effects.

Some patients with blood cancer are treated with a stem cell transplant, in which cells from a healthy donor are infused into their bloodstream with the intent that those cells will travel to the bone marrow and form new healthy blood cells. Frequently, however, when donors are unrelated, their cells identify the recipients as foreign, prompting them to attack organs and tissues. Treatment with systemic corticosteroids can help control the severity of the condition. But in up to 90 percent of aGVHD patients who dont respond to steroid treatment, the condition can prove fatal.

MesoBlasts submission was based on a clinical trial that enrolled 55 children age 2 months to 17 years who had received a transplant of bone marrow, peripheral blood stem cells, or cord blood, were diagnosed with aGVDH and werent responding to steroid therapy. The study tracked their responses to remestemcel on day 28. Overall, 70 percent of the patients responded, including 76 percent of the 25 patients whose condition was graded as most severe. On day 100, 74 percent of patients remained alive; on day 180, 69 percent.

However, the trial was neither randomized nor controlled, raising concerns of confounding factors and potential bias. MesoBlast said investigators werent willing to enroll children in such a trial. But the company said randomization and controlled design would be incorporated into a planned post-marketing study in adults.

In previous clinical trials in wider patient populations, the treatment missed the primary goal. Analyses of results from those earlier trials prompted MesoBlasts decision to focus the drugs further development to steroid-refractory pediatric patients. In its presentation to the advisory panel the company said the remestemcel manufacturing process has been improved since those trials in ways that have made the treatment more potent.

The panel voted on whether MesoBlast provided enough clinical data to show that its therapy was effective in treating aGVHD in this narrower group. Panelist Christian Hinrichs, a clinical researcher at the National Cancer Institute and physician by training, was the sole no vote. Nine panelists felt the available data did indicate efficacy. (The committee recorded the tally as 8-2, but a MesoBlast representative said one no vote was made in error.)

I do think that the two prior randomized trials convincingly show that the [earlier version of remestemcel], at least in the population that was being studied, which is similar but not the same, clearly did not have meaningful activity, Hinrichs said. So, you know, do we think that these tweaks to the manufacturing have suddenly made it highly effective, and the change in patient population has suddenly made it highly effective?

Jorge Garcia, division chief of solid tumor oncology at University Hospitals Seidman Cancer Center in Cleveland, however, said while it isnt clear how the treatment compares to other drugs used to treat patients with the condition, the data indicate it is safe and has shown some efficacy.

In May 2019 an Incyte (NASDAQ: INCY) treatment, ruxolitinib (Jakafi), became the first FDA-approved treatment for patients with aGVHD who didnt responded to steroid therapy. Ruxolitinib was OKd for patients starting at age 12. But no treatment is approved for those younger.

Although the FDA considers advisory panel recommendations during drug reviews, committee recommendations are not binding, and the agency doesnt always follow them. Its decision on remestemcel is anticipated by Septembers end.

Image: iStock/Yarygin

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

Read the original post:
Advisory Body Backs MesoBlast Therapy for Transplant Complication - Xconomy

Stem Cell Therapy: A Ray of Hope to End Global Pandemic of COVID-19 | Roots Analysis – Bulletin Line

By Stem Cell Treatment

I would never have thought that a mutant flu virus could create that big panic in people at each and every corner of the world. In fact, the past few days in quarantine have really made me realize where exactly the humanity is heading. For majority of us, our lives are on a temporary hold while the world is dealing with the global pandemic of COVID-19. In fact, past three months have served as something of an inflection for many countries and as the number of infected patients have surpassed one million, there is already a sense of worry looming across the industries.

Since Coronavirus is a newly identified pathogen, there is no known pre-existing immunity observed in humans and therefore everyone is assumed to be susceptible. While researchers all across the globe are putting efforts to develop immediate treatment, there are speculations, based on credible evidence, that infected patients treated with Stem Cell Therapy are more likely to survive the disease. Specifically, mesenchymal stem cells can be effectively used to improve patients resistance to the SARS-CoV-2 virus induced pneumonia as these cells have the potential to repair damaged tissues in the patients respiratory system leading to speedy recovery.

For More Insights Click Here

Recent Trends

Recent trends across several social medial platform highlight the immense efforts put by several stakeholders validating the therapeutic potential of stem cells. Specifically, Id like to appreciate the efforts of Azidus Brasil, CAR-T (Shanghai) Biotechnology, Janssen Research & Development, Mesoblast, Millennium Pharmaceutical, Pfizer, Stem Cell Arabia, Tianhe Stem Cell Biotechnologies and Tuohua Biological Technology that have progressed significantly in-terms of development of stem cell-based therapies to defeat this global pandemic of COVID-19 infection.

Looking at the efforts made by different pharmaceutical companies, I felt assured and hopeful as many patients have successfully recovered, while others are at the verge of getting discharged by using these novel classes of regenerative medicines.

What are the Key Hubs for Stem Cell Research?

With the virus strengthening its foothold in several countries across the globe, the threat of pandemic has become real and the question is are we ready?

As per the recent study published by Roots Analysis, the efforts for development of stem cell therapies have been undertaken by players all across the globe, majority of the developers (45%) are based in Asia-Pacific regions; China, South Korea and Japan; followed by developed countries, such as the US, Germany, Belgium, Spain and the UK.

Roots Analysis, in its recent report, has captured the clinical and research landscape of stem cell therapy-based treatment. To know further, check out the report here

Expert Opinion

In fact. several industry stakeholders are quite optimistic about the future market potential of stem cell-based therapies.

Bottom Line: Stay Cautious, Stay Hopeful!!

In the midst of the anxiety, worry, and uncertainty surrounding the COVID-19 pandemic, each day seems to bring news thats worse than the day before. However, remember this is not for the first time any pandemic outbreak has taken place in the history of mankind. About 200,000 (~20%) patients have already been recovered from this disease. The sky is not falling and for sure, life would return to normal. Stay cautious, stay hopeful.

For further information, check out the report here

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

View original post here:
Stem Cell Therapy: A Ray of Hope to End Global Pandemic of COVID-19 | Roots Analysis - Bulletin Line

→←